Skip to main content
OpenTrials
Completed

NCT Number: NCT04978285

Association of Postoperative Anaemia With Patient-centred Outcomes

Primary aim - To investigate the relationship between postoperative anaemia and patient-centred outcomes after major abdominal surgery.

Secondary aim - To determine whether a more liberal perioperative IV fluid strategy increases the risk of postoperative anaemia (haemodilution).

Hypothesis: Adults with anaemia in the immediate postoperative period following major abdominal surgery have a poorer quality of recovery and higher risk of complications, leading to poor disability-free survival when compared with patients without postoperative anaemia.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Alfred Hospital

Melbourne, Victoria, 3004, Australia

About this study

The consequences of postoperative anemia remain unclear. Postoperative anaemia is more likely if there is pre-existing anemia, but also increased perioperative blood loss, frequent blood sampling, excess IV fluids (leading to hemodilution), sepsis, and inadequate nutritional intake after surgery. A nadir in Hb concentration is most often observed within the first 3-4 days after surgery. Postoperative anemia is believed to have deleterious effects on patient outcomes, including prolonged hospital stay, increased postoperative complications, and perhaps poor survival, but there is very little data to support this belief.

A recent consensus statement suggested that all patients recovering from major surgery (defined as blood loss > 500 ml or lasting > 2 h) and either had preoperative anemia or moderate-to-severe blood loss during surgery must be screened for anemia after surgery. Furthermore, this consensus group recommended that patients recovering from uncomplicated major surgery should have their Hb concentration measured for at least 3 days after surgery to detect anemia. As outlined above, this is problematic if there is fluid retention.

The role of IV iron for the treatment of postoperative anemia is unclear, with the most recent systematic review concluding that neither oral nor IV iron had a significant effect on patient quality of life or functional outcomes following surgery. A diagnosis of iron deficiency is very difficult in the postoperative period because the acute phase inflammatory response results in spuriously elevated ferritin levels, and several studies have demonstrated oral iron therapy is ineffective in this setting.

The investigators propose a study to investigate the incidence, extent, and outcomes of patients with anemia after major surgery, including an assessment of the amount of IV fluids administered in the immediate perioperative period.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults (≥18 years) undergoing elective major surgery and providing informed consent
  • All types of open or lap-assisted abdominal or pelvic surgery with an expected duration of at least 2 hours, and an expected hospital stay of at least 3 days
  • At increased risk of postoperative complications, as defined by any of the following criteria:
  • age ≥70 years
  • known or documented history of coronary artery disease
  • known or documented history of heart failure
  • diabetes currently treated with an oral hypoglycemic agent and/or insulin
  • preoperative serum creatinine >200 micromol/L (>2.8 mg/dl)
  • morbid obesity (BMI ≥35 kg/m2)
  • preoperative serum albumin <30 g/L
  • anaerobic threshold (if done) <12 mL/kg/min
  • or two or more of the following risk factors:
  • ASA 3 or 4
  • chronic respiratory disease
  • obesity (BMI 30-35 kg/m2)
  • aortic or peripheral vascular disease
  • preoperative Hb <100 g/L
  • preoperative serum creatinine 150-199 micromol/L (>1.7 mg/dl)
  • anerobic threshold (if done) 12-14 mL/kg/min

Exclusion criteria

  • Urgent or time-critical surgery
  • ASA physical status 5 - such patients are not expected to survive with or without surgery, and their underlying illness is expected to have an overwhelming effect on outcome (irrespective of fluid therapy)
  • Chronic renal failure requiring dialysis
  • Pulmonary or cardiac surgery - different pathophysiology, and thoracic surgery typically have strict fluid restrictions
  • Liver resection - most units have strict fluid/CVP limits in place and won't allow randomisation
  • Minor or intermediate surgery, such as laparoscopic cholecystectomy, transurethral resection of the prostate, inguinal hernia repair, splenectomy, closure of colostomy - each of these are typically "minor" surgery with minimal IV fluid requirements, generally low rates of complications and mostly very good survival.

Treatment and study plan

Anemia

Other

Depends on Day 3 Hb result

Other names: Observational

Primary outcomes

  1. Persistent disability or death by 90 days

    Time frame: 90 days after surgery

    Defined as a World Health Organization Disability Assessment Schedule 2.0 (WHODAS) score of at least 24 points (on the 48-point scale) at both 30 and 90 days postoperatively, reflecting a disability level of at least 25% and being the threshold point between "disabled" and "not disabled" as per WHO guidelines. Disability was assessed by the participant, but if unable then we used the proxy's report.

Secondary outcomes

  1. Death: all-cause mortality at 90 days, then up to 12 months after surgery

    Time frame: 1 year

  2. A composite (pooled) and individual septic complications: sepsis, surgical site infection, anastomotic leak, and pneumonia

    Time frame: 30 days

  3. Sepsis: using Centers for Disease Control and Prevention (CDC) with National Healthcare Safety Network (NHSN) criteria

    Time frame: 30 days

  4. Surgical site infection

    Time frame: 30 days

    CDC criteria

  5. Pneumonia

    Time frame: 30 days

    The presence of new and/or progressive pulmonary infiltrates on chest radiograph plus two or more of the following:

    i. Fever ≥ 38.5°C or postoperative hypothermia <36°C ii. Leucocytosis ≥ 12,000 WBC/mm3 or leucopenia < 4,000 WBC/mm3 iii. Purulent sputum and/or iv. New onset or worsening cough or dyspnea.

  6. Anastomotic leak

    Time frame: 30 days

    A defect of the intestinal wall at the anastomotic site (including suture and staple lines of neorectal reservoirs) leading to a communication between the intra- an extra luminal compartments.

  7. Acute kidney injury

    Time frame: 30 days

    According to The Kidney Disease: Improving Global Outcomes (KDIGO) group criteria, but not urine output - for Stage 2 or worse AKI defined as at least 2-fold increase in creatinine, or estimated GFR decrease >50%

  8. Unplanned admission to ICU within 30 days of surgery

    Time frame: 30 days

  9. ICU stay

    Time frame: 30 days

    Total days - additive, including initial ICU admission and readmission times up to Day 30

  10. Hospital stay

    Time frame: 30 days

    Total -additive, from the start (date, time) of surgery until actual hospital discharge , plus readmission(s) up to Day 30

  11. Quality of recovery

    Time frame: Postoperative Days 3 and 30

    QoR-15 scale score

  12. Hospital re-admission

    Time frame: At 3, 6 and 12 months.

Sponsors and collaborators

Lead sponsor

Bayside Health

Other Gov

Collaborators

  • Monash University

Registry information

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Jul 27, 2021
Registry last updated
Jul 13, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.